Board of Directors

Glenn Larsen, Ph.D.

Founder & Chairman, 180 Therapeutics

Glenn Larsen, Ph.D., is a founder of 180 Therapeutics and joined as Chairman in September 2013, and currently is President & CEO of Aquinnah Pharmaceuticals, a company developing therapies for ALS and Alzheimer’s disease. Glenn has over 25 years of experience in business, research and drug development in the biotechnology and pharmaceutical industry, including raising approximately $80 million in private venture and grant funding. Glenn has been closely involved with the commercial registration of five biologics and advancing over 15 new biologic or small molecule chemical entities to clinical development. Past positions include Vice President of Musculoskeletal Sciences at Wyeth (Pfizer), directing R&D for the second largest therapeutic area in the fields of arthritis, inflammation and tissue regeneration. Glenn also co-chaired the Musculoskeletal Therapeutic Franchise with responsibility for directing Wyeth’s global commercial and development efforts for Enbrel, an anti-TNF therapeutic, and was a member of Wyeth’s Executive Global Development Team, responsible for directing all of Wyeth’s therapeutic programs. Dr. Larsen also served as Vice President of Preclinical Research and Development at Genetics Institute, responsible for all preclinical activities and regulatory requirements needed to identify and advance drug candidates to clinical trials for evaluation in the fields of oncology, inflammation, immunology, hemophilia, hematopoiesis and tissue regeneration, including the BMP-2 (Infuse) bone osteoinduction program. Dr. Larsen also served on the Board of Directors of Hydra Biosciences and held other senior executive roles at Hydra Biosciences and SpringLeaf Therapeutics. Dr. Larsen received his Ph.D. in Biochemistry from Stony Brook University and is a PMD graduate of Harvard Business School.

Sir Marc Feldmann, MB BS, BSc (Med) Hons, PhD, MD (Hon Causa), DMSc (Hon Causa), FRCPath, FRCP

Founder, 180 Therapeutics
Professor, University of Oxford, UK

Sir Marc Feldmann, MB BS, BSc (Med) Hons, PhD, MD (Hon Causa), DMSc (Hon Causa), FRCPath, FRCP, is a founder of 180 Therapeutics and Professor at the University of Oxford in the U.K. Marc Feldmann’s initial studies in medicine at University of Melbourne were followed by a PhD with Sir Gus Nossal at Walter and Eliza Hall Institute where he investigated in vitro immune responses and immune regulation. Subsequent work in London led to the generation of a new hypothesis for mechanisms of autoimmunity linking up regulated antigen presentation and cytokine expression. Testing this hypothesis led to the discovery, with his colleague Ravinder Maini, of the pivotal role of TNF in the pathogenesis of rheumatoid arthritis (RA), which was established by studying synovial cultures from patients, animal models and clinical trials. This major discovery has revolutionized therapy not only of RA but other chronic inflammatory diseases and helped change the perception of monoclonal antibodies from niche products to a mainstream therapeutic category. Current interests are to work with colleagues to define new treatments for unmet needs, e.g. fibrosis and fractures with Prof. Nanchahal. The other major interest is towards more cost-effective therapy of RA and trying to get closer to a cure. Professor Feldmann has received numerous international awards for this pioneering work including the Crafoord Prize of the Royal Swedish Academy, and the Albert Lasker Clinical Medical Research Award, together with Professor Sir Ravinder Maini. In addition, Professor Feldmann has been Knighted by the Queen of England for this work and in 2007 he was named European Inventor of the Year in the lifetime achievement category, the first time this award was given for biomedicine. He is a member of a number of prestigious academies of science, the Royal Society and Academy of Medical Science in UK, the National Academy of Science USA as a foreign associate, and the Australian Academy of Science as a corresponding member.

James R. Gorman, M.D., Ph.D.

Board Member

James Gorman, M.D., Ph.D. is Visiting Scholar at Wyss Institute at Harvard, and Strategic Advisor at Engine Biosciences, and Director of 180 Therapeutics. Dr. Gorman was previously Vice President, Corporate Development and Strategy at Agenus, where he led corporate development, strategy, and portfolio planning for the company’s diverse pipeline of clinical and pre-clinical immune-oncology drugs. Dr. Gorman was previously co-founder and CEO of 121 Bio, a venture backed company developing immune-oncology biologics and diagnostics, which was acquired by Agenus in 2016. Prior to 121 Bio, Dr. Gorman founded BioAssets Development Corporation (BDC) in 2005 with Dr. Robert Kamen, where he was CEO & Chief Medical Officer. BDC’s lead program tested an injectable tumor necrosis factor (TNF) inhibitor in Phase I-II clinical trials for the treatment of sciatic pain in patients with disk herniation. The program was the focus of a $30 million option agreement with Cephalon on the company’s anti-TNF program, and subsequent acquisition by Cephalon. Prior to BDC, Dr. Gorman spent seven years in licensing and strategic initiatives at Abbott Laboratories, where he was responsible for strategy to grow Abbott’s biologics business and received an Abbott President’s Award for his role in the acquisition of the blockbuster anti-TNF antibody Humira® and the biologics platform, resulting from Abbott’s $7 billion acquisition of BASF Pharmaceuticals in 2001. Dr. Gorman obtained his M.D. degree and his Ph.D. degree in Immunology from Harvard Medical Harvard Medical School’s M.D.- Ph.D. program and graduated summa cum laude from Yale University with B.A. and M.S. degrees in biology.